FDA finishes device review in four monthsMedical imaging vendors are enjoying a rare burst of productivityfrom Food and Drug Administration product reviewers, who havebeen granting marketing clearance to imaging devices at a frenziedpace this
Medical imaging vendors are enjoying a rare burst of productivityfrom Food and Drug Administration product reviewers, who havebeen granting marketing clearance to imaging devices at a frenziedpace this year. The latest winner in the device review lotteryis Siemens Medical Systems. The German vendor received word lastmonth of FDA clearance for Magnetom Open, a 0.2-tesla scannercapable of interventional MRI procedures. The FDA's action cameonly four months after Open's 510(k) application was filed.
Magnetom Open was introduced at the Radiological Society ofNorth America meeting last year (SCAN 11/17/93). The system, whichemploys resistive magnet technology and actively shielded gradients,is shaped like a giant C-arm to give clinicians access to patients.
Siemens hopes to use Open to forge new ground in interventionalMRI, but has plans for the scanner beyond this still-emergingniche. The vendor will also market Open as a cost-effective systemthat can pay for itself with traditional MRI procedures whileclinicians explore the utility of interventional scanning. Siemensplans to set the unit's list price under $1 million.
One of Magnetom Open's beta sites will be the newly formedCenter for Interventional MRI at the University of Californiaat Los Angeles. There, clinicians will use Open for MRI-guidedradio-frequency thermal ablation of primary and metastatic braintumors (SCAN 3/2/94).
Siemens competitor GE Medical Systems is also developing aninterventional MRI scanner, Signa MRT. The system has a superconducting0.5-tesla magnet in a "double doughnut" shape to facilitateaccess to the patient. Unlike Open, the GE system will be dedicatedto interventional procedures.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.